Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05932563
Other study ID # HVAC2301
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2023
Est. completion date December 31, 2024

Study information

Verified date June 2023
Source Fujian Maternity and Child Health Hospital
Contact Binhua Dong
Phone 13599071900
Email dbh18-jy@126.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Human papillomavirus (HPV) is currently one of the most common sexually transmitted infections, according to its carcinogenicity is divided into high-risk genotypes and low-risk genotypes, studies have confirmed that carcinogenic HPV type continuous infection leads to higher incidence of condyloma acuminatum and cervical cancer, while increasing the risk of oropharyngeal cancer, vaginal cancer and other related cancers. Human papillomavirus vaccines have been widely used worldwide to prevent cancers of the lower reproductive tract, such as cervical, anal and vulvar cancers. According to the type, it is divided into domestic two-valent (Vantage), imported two-valent (GlaxoSmithKline), four-valent (Merck) and nine-valent (Merck)HPV vaccines. All four vaccines prevent high-risk HPV 16/18 infection, and there are differences between the quadrivalent and nine-valent HPV vaccine prevention genotypes. The protection rate, immunizing target and immunizing procedure of different valence number are slightly different. Studies have shown that after women receive HPV vaccine, the incidence of arm redness, swelling, fever, pain and other adverse reactions is high, often accompanied by menstrual disorders, sleep problems, emotional irritability, fever, dizziness, headache and other adverse reactions. However, the causal relationship between HPV vaccination and symptoms after vaccination at different prices is controversial, and there is little research in this area. Therefore, we intend to design a multicenter, bidirectional cohort study to investigate the relationship between HPV vaccination with different valence numbers and adverse reactions after vaccination in Chinese women, and to further explore the unknown potential factors affecting the protective effect of HPV vaccine.


Description:

Based on the database with HPV typing results before HPV vaccination, this study will follow up the population's epidemiological characteristics such as adverse reaction symptoms after HPV vaccination through telephone or face to face, and collect 1 cervical exfoliated cell and 1 peripheral blood tube (5ml) for HPV genotyping detection and HPV neutralizing antibody detection. Meanwhile, participants were recruited in different regions of China for a period of three months. Follow-up was performed at the time of the first dose of HPV vaccine, 1 month after the third dose, and 12 months after the third dose. The corresponding questionnaire was filled in during enrollment and follow-up, and one cervical exfoliated cell was collected at each of the three follow-up visits for HPV genotyping. At the same time, the peripheral blood tubes were collected one month after the third injection to evaluate the effect of HPV vaccine neutralizing antibodies. The multi-center cohort study was conducted to explore the unknown potential factors affecting the protective effect of HPV vaccine, and the relationship between HPV vaccine with different price and adverse reactions after vaccination in Chinese women.


Recruitment information / eligibility

Status Recruiting
Enrollment 1700
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 9 Years to 45 Years
Eligibility Inclusion Criteria: - The retrospective cohort must meet the following conditions: 1. HPV typing results before HPV vaccination; 2. Willing to go to the main center of Fujian Provincial Maternal and Child Health Hospital or branch center for free examination. Prospective cohort population must meet the following conditions: 1. Female, 9-45 years old (sexual life history); 2. In the next two years, I am willing to go to the main center of Fujian Provincial Maternal and Child Health Hospital or sub-centers for free check-ups; 3. Will receive the first dose of HPV vaccine; 4. There is no abnormal psychological or physical condition before HPV vaccination. Exclusion Criteria: 1. Subjects who have previously received another commercially available HPV vaccine, or participated in a clinical study of HPV vaccine, or participated in a clinical study of another vaccine within the past 6 months; 2. Women who plan to become pregnant within the next two years; 3. Are immune deficient or have been diagnosed with congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, SLE, rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease, or other autoimmune disease, and have received immunosuppressive therapy within the past 6 months; 4. Subjects with a history of epilepsy, psychosis, medically treatable major depression, convulsions or convulsions, or subjects with a family history of psychosis; 5. Subjects with spleen insufficiency, functional spleen insufficiency, and any disease that results in spleen insufficiency or splenectomy; 6. During the follow-up period, they were not willing to return to the main center or sub-center of the Fujian Maternal and Child Health Hospital to collect cervical exuded cells and/or peripheral blood samples, such as 30-60 days or 12 months after the last HPV vaccination. 7. Pregnant or lactating women; 8. Asexual life history; 9. The investigator believes that there are other factors that are not suitable for participants to participate in clinical trials.

Study Design


Locations

Country Name City State
China Xiangya Hospital, Central South University Changsha Hunan
China Fujian Maternity and Child Health Hospital Fuzhou Fujian
China Fujian Provincial Center for Disease Control and Prevention Fuzhou Fujian
China Fuzhou Shanghai street community health Service center Fuzhou Fujian
China Shenzhen Maternal and Child Health Hospital Shenzhen Guangdong
China Hubei Maternal and Child HealthCare Hospital Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Fujian Maternity and Child Health Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Human Papillomavirus (HPV) genotyping tests All participants were tested for human oncovirus (HPV) genotyping prior to the first dose of HPV vaccination Baseline (Before the first dose of HPV vaccination)
Primary Human Papillomavirus (HPV) genotyping tests Prospective cohort subjects underwent Human Papillomavirus (HPV) genotyping tests at one month after the third dose of HPV vaccination one month after the third dose of HPV vaccination
Primary Human Papillomavirus (HPV) genotyping tests Prospective cohort subjects underwent Human Papillomavirus (HPV) genotyping tests at 12-month after the third dose of HPV vaccination 12-month after the third dose of HPV vaccination
Primary HPV vaccine neutralizing antibody detection Prospective cohort subjects were tested for neutralizing antibodies to the HPV vaccine at one month after the third dose of HPV vaccination one month after the third dose of HPV vaccination
Primary Human Papillomavirus (HPV) genotyping tests Participants in the retrospective cohort were tested for human oncovirus (HPV) genotyping 1-12 months after the third dose of HPV vaccination 1 to 12 months after the third dose of HPV vaccination
Primary HPV vaccine neutralizing antibody detection Participants in the retrospective cohort were tested for HPV vaccine neutralizing antibodies 1-12 months after the third dose of HPV vaccine 1 to 12 months after the third dose of HPV vaccination
See also
  Status Clinical Trial Phase
Completed NCT05035888 - Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension N/A
Completed NCT04028791 - Sickle Cell Trait and Exercise, Effect of Hot Environment N/A
Completed NCT04556357 - Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia N/A
Completed NCT04118322 - The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy N/A
Recruiting NCT03456544 - Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
Completed NCT03723109 - Airway Management During TCI vs RSI Anesthesia Induction
Completed NCT03316417 - Study of Adverse Renal Effects of Immune Checkpoints Inhibitors
Completed NCT05712018 - Comparison of Different HES Coload Volumes on the 90% ED of Norepinephrine N/A
Not yet recruiting NCT04576663 - Phenylephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia N/A
Completed NCT03006042 - Pharmacokinetics of BPV Following Bilateral US-guided TAP Block for C-section N/A
Completed NCT03011775 - Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease Phase 4
Completed NCT04556370 - Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension in Parturients With Preeclampsia. N/A
Completed NCT03706755 - Comparison of Two Doses of Norepinephrine in Preventing Hypotension After Spinal Anesthesia Phase 4
Completed NCT02854787 - Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia Phase 4
Completed NCT02768168 - The Effects of Dezocine Pretreatment on Dexamethasone Induced Perineal Irritation N/A
Completed NCT04272567 - Norepinephrine Prophylaxis for Postspinal Anesthesia Hypotension N/A
Recruiting NCT05310331 - Donafenib for Recurrent Cervical Cancer Phase 2
Completed NCT05690334 - Different Crystalloid Coload Volumes on the 90% ED of Norepinephrine N/A
Not yet recruiting NCT06467045 - Frequency of Adverse Events in Pediatric Patients Receiving Sedation for Magnetic Resonance Imaging
Completed NCT05475873 - Ondansetron for Postspinal Anesthesia Hypotension N/A